Literature DB >> 23190210

Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.

Jean-Pascal Fournier1, Agnès Sommet, Geneviève Durrieu, Jean-Christophe Poutrain, Maryse Lapeyre-Mestre, Jean-Louis Montastruc.   

Abstract

Drug-drug interactions (DDIs) between antihypertensive drugs and non-steroidal anti-inflammatory drugs (NSAIDs) can lead to adverse drug reactions (ADRs). Guidelines are available to help prescribers deal with these drug associations, but their implementation is not well evaluated. The aims of this study were to assess the prevalence of NSAIDs exposure in patients treated with antihypertensive drugs, using the French Pharmacovigilance database, and explore the ADRs related to DDIs between antihypertensive drugs and NSAIDs. Over the 11, 442 notifications of ADRs recorded in this database in patients treated with oral antihypertensive drugs between 2008 and 2010, 517 (4.5 and 95% CI: 4.1-4.9) also included exposure to NSAIDs. These subjects were more frequently women, took more drugs in general, and were younger and less frequently treated with antiplatelet drugs. In 24.2% of them (125 patients), a DDI between NSAIDs and antihypertensive drugs was potentially the cause of the reported ADR. Acute renal failure caused by DDIs between NSAIDs and angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or diuretics was the most frequently reported ADR (20.7%). Finally, in the French Pharmacovigilance database, around one-fourth of associations NSAIDs  +  antihypertensive drugs are associated with a 'serious' ADR (mainly acute renal failure), suggesting that this well-known DDI is not enough taken into account by prescribers.
© 2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  Pharmacovigilance; acute kidney injury; antihypertensive agents; drug interactions; non-steroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2012        PMID: 23190210     DOI: 10.1111/fcp.12014

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  Drug-drug interaction software in clinical practice: a systematic review.

Authors:  Tina Roblek; Tomaz Vaupotic; Ales Mrhar; Mitja Lainscak
Journal:  Eur J Clin Pharmacol       Date:  2014-12-23       Impact factor: 2.953

Review 2.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

Review 3.  Neuroinflammation as a mechanism linking hypertension with the increased risk of Alzheimer's disease.

Authors:  Ekta Bajwa; Andis Klegeris
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

4.  Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease.

Authors:  Zachary Bouck; Graham C Mecredy; Noah M Ivers; Moumita Barua; Danielle Martin; Peter C Austin; Joshua Tepper; R Sacha Bhatia
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

5.  Safety concerns in simultaneous use of prescription and 'over-the-counter' medicines- results of patient survey in Estonia.

Authors:  Maia Gavronski; Daisy Volmer
Journal:  Springerplus       Date:  2014-03-17

6.  Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study.

Authors:  Hannelore Sprenger-Mähr; Emanuel Zitt; Karl Lhotta
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

7.  Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase.

Authors:  Mohammad Bakhriansyah; Ronald H B Meyboom; Patrick C Souverein; Anthonius de Boer; Olaf H Klungel
Journal:  Fundam Clin Pharmacol       Date:  2019-04-22       Impact factor: 2.748

8.  Safety and efficacy of skin patches containing loxoprofen sodium in diabetic patients with overt nephropathy.

Authors:  Hisazumi Araki; Shogo Kuwagata; Mariko Soumura; Kosuke Yamahara; Yoshikata Morita; Shinji Kume; Keiji Isshiki; Shin-ichi Araki; Atsunori Kashiwagi; Hiroshi Maegawa; Takashi Uzu
Journal:  Clin Exp Nephrol       Date:  2013-08-07       Impact factor: 2.801

9.  [Pharmaceutical intervention to reduce the iatrogenic risk associated with the triple whammy combination].

Authors:  Gemma Arrufat-Goterris; Fernando do Pazo-Oubiña; María Malpartida-Flores; Raquel María Rodríguez-Rincón
Journal:  Aten Primaria       Date:  2016-07-13       Impact factor: 1.137

10.  ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study.

Authors:  Laurie A Tomlinson; Gary A Abel; Afzal N Chaudhry; Charles R Tomson; Ian B Wilkinson; Martin O Roland; Rupert A Payne
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.